-
1
المؤلفون: Serafina Guadagnuolo, Michele Bartoletti, Alessandro Broccoli, Ginevra Lolli, Elena Sabattini, Vittorio Stefoni, Michele Dicataldo, Lisa Argnani, Beatrice Casadei, Maria Guarino, Alice Morigi, Stefano Fanti, Elisabetta Pierucci, Laura Nanni, Pier Luigi Zinzani, Francesca Bonifazi, Cinzia Pellegrini, Luca Spinardi
المساهمون: Casadei B, Argnani L, Guadagnuolo S, Pellegrini C, Stefoni V, Broccoli A, Nanni L, Morigi A, Lolli G, Guarino M, Spinardi L, Pierucci E, Fanti S, Bartoletti M, Dicataldo M, Sabattini E, Bonifazi F, Zinzani PL.
المصدر: Cancers
Volume 13
Issue 19
Cancers, Vol 13, Iss 4789, p 4789 (2021)مصطلحات موضوعية: Oncology, large B-cell non-Hodgkin lymphoma, Cancer Research, medicine.medical_specialty, business.industry, CAR T-cell therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Leukapheresis, medicine.disease, Chimeric antigen receptor, Article, Lymphoma, Cytokine release syndrome, Refractory, Chemoimmunotherapy, Internal medicine, medicine, B-Cell Non-Hodgkin Lymphoma, Rituximab, business, RC254-282, relapsed/refractory lymphoma, medicine.drug
الوصف: Simple Summary CAR T-cell therapies have undoubtedly revolutionized the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. These therapies represent a valuable new treatment option, yielding impressive complete remission rates and improving survival. The aim of this article is to give an overview of emerging real-world evidence since data from every-day clinical practice are still scarce. We report effectiveness and safety data on 30 patients treated at our Institution. Treatment in this setting with CD19-targeted CAR T-cell therapies for relapsed/refractory B-cell non-Hodgkin lymphoma showed a manageable safety profile and high objective response rate, confirming the encouraging results of the pivotal clinical trials. Abstract Large B-cell lymphomas (LBCL) are the most common types of non-Hodgkin lymphoma. Although outcomes have improved thanks to the introduction of rituximab-based chemoimmunotherapy, certain LBCL still represents a challenge because of initial resistance to therapy or recurrent relapses. Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapies approved for patients with relapsed/refractory (R/R) LBCL, based on the results of phase II pivotal single-arm trials ZUMA-1 (for axi-cel) and JULIET (for tisa-cel). Here, we report patients outcomes with axi-cel and tisa-cel in the standard of care (SoC) setting for R/R LBCL, treated at our Institution. Data were collected from patients who underwent leukapheresis between August 2019 and February 2021. Toxicities were graded and managed according to the institution’s guidelines. Responses were assessed as per Lugano 2014 classification. Of the 30 patients who underwent leukapheresis, 18 (60%) received axi-cel, while 12 (40%) tisa-cel. Grade 3 or higher cytokine release syndrome and neurotoxicity occurred in 10% and 16% patients, respectively. Best objective and complete response rates were 73.3% and 40%, respectively. Treatment in SoC setting with CD19 CAR T-cell therapies for R/R LBCL showed a manageable safety profile and high objective response rate.
وصف الملف: STAMPA; application/pdf
إعادة تعيين المنقحات
عرض المنقحات (%%عد%%)